Showing 731-740 of 1226 results for "".
- Frontera Therapeutics Completes $160 Million Series B Financing to Fund Clinical Development and Manufacturing Capabilitieshttps://modernod.com/news/frontera-therapeutics-completes-160-million-series-b-financing-to-fund-clinical-development-and-manufacturing-capabilities/2480975/Frontera Therapeutics announced successful completion of a $160 million Series B funding round. In addition, Frontera announced that the FDA has accepted the company’s investigational new drug (IND) application to initiate a first-in-human clinical trial of FT
- Nacuity Pharmaceuticals Announces $16.5 Million Series B Financing Led by Foundation Fighting Blindness & RD Fundhttps://modernod.com/news/nacuity-pharmaceuticals-announces-165-million-series-b-financing-led-by-foundation-fighting-blindness-rd-fund/2480913/Nacuity Pharmaceuticals announced the closing of a $16.5 million Series B financing led by Foundation Fighting Blindness and its venture arm RD Fund. Additional existing investors also participated in the round. Proceeds from the financing will be used to support the advanc
- Sydnexis Secures $45 Million Series B Financing to Advance Myopia Drug Candidatehttps://modernod.com/news/sydnexis-secures-45-million-series-b-financing/2479442/Sydnexis announced the completion of a $45 million Series B financing to fund Sydnexis’ lead candidate, SYD-101, through completion of the fully enrolled pivotal Phase 3 STAAR study for the treatment of progressive myopia in children. The financing was led by Visionary Ventures, Blue Stem
- AffaMed Therapeutics Completes $170 Million Series B Financing to Further Development of Ophthalmic and Neuroscience Pipelinehttps://modernod.com/news/affamed-therapeutics-completes-170-million-series-b-financing-to-further-development-of-ophthalmic-and-neuroscience-pipeline/2479029/AffaMed Therapeutics announced the completion of over $170 million in Series B financing. Proceeds from the financing will be used to advance clinical development of AffaMed’s pipeline of innovative therapeutic candidates, progress business development and partnering activities, and support
- EyeQue Raises $11.2 Million in Series B to Bring At-Home Vision Testing to the Masseshttps://modernod.com/news/eyeque-raises-11-2-million-in-series-b-to-bring-at-home-vision-testing-to-the-masses/2480065/EyeQue announced it has raised $11.2 million in a Series B round from existing investors. The funds will be used to help the company on its mission to eliminate extraneous trips to the optometrist and make at-home vision testing a reality for people across the globe. EyeQue’s patented technology
- Nordic Group Appoints Eric Donnenfeld, MD, as Medical Advisory Board Chairhttps://modernod.com/news/nordic-group-appoints-eric-donnenfeld-md-as-medical-advisory-board-chair/2482132/Amring Pharmaceuticals, a subsidiary of Nordic Group, announced that ophthalmologist Eric D. Donnenfeld, MD, will chair its US Medical Advisory Board, which includes Richard Lindstrom, MD (Minnesota), Vance Thompson, MD (South Dakota), Preeya Gupta, MD (North Carolina), Paul Karpecki, O
- Nacuity Pharmaceuticals Strengthens Scientific Advisory Board with Appointment of Nancy Holekamp, MD, and Richard L. Lindstrom, MDhttps://modernod.com/news/nacuity-pharmaceuticals-strengthens-scientific-advisory-board-with-appointment-of-nancy-holekamp-md-and-richard-l-lindstrom-md/2480903/Nacuity Pharmaceuticals announced the expansion of its Scientific Advisory Board (SAB) with the appointment of Nancy Holekamp, MD, and Richard L. Lindstrom, MD. “We are thrilled and grateful to welcome two world-renowned ophthalmologists who bring to our SAB significant and essent
- Elizabeth Yeu, MD, and K. Peony Yu, MD, Appointed to Staar Surgical Board of Directorshttps://modernod.com/news/elizabeth-yeu-md-and-k-peony-yu-md-appointed-to-staar-surgical-board-of-directors/2478798/Staar Surgical announced the appointments of Elizabeth Yeu, MD, Partner, Virginia Eye Consultants, and K. Peony Yu, MD, retired Chief Medical Officer, FibroGen, to its Board of Directors, effective January 21, 2021. “The addition of Dr. Elizabeth Yeu and Dr. K. Peony Yu to our Board of Dir
- Second Sight Announces Departure of Will McGuire, President and CEO, and Appointment of Gregg Williams as Acting CEOhttps://modernod.com/news/second-sight-announces-departure-of-will-mcguire-president-and-ceo-and-appointment-of-gregg-williams-as-acting-ceo/2477384/Second Sight Medical Products announced the departure of Will McGuire, President and Chief Executive Officer, effective March 27, 2020, to pursue another professional opportunity located closer to his family. Mr. McGuire remains as a director on Second Sight’s board. Effective March 27, 20
- Oxurion Announces the Continuation of KALAHARI Phase 2, Part B Study in DME Following Interim Analysishttps://modernod.com/news/oxurion-announces-the-continuation-of-kalahari-phase-2-part-b-study-in-dme-following-interim-analysis/2481293/Oxurion NV announced that an Independent Data Monitoring Committee (IDMC) completed its planned interim analysis of the KALAHARI phase 2, Part B clinical trial evaluating Oxurion’s novel plasma kallikrein (PKal) candidate, THR